SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 1,526.22 |
| Enterprise Value ($M) | 1,470.35 |
| Book Value ($M) | 378.10 |
| Book Value / Share | 2.72 |
| Price / Book | 4.04 |
| NCAV ($M) | 376.01 |
| NCAV / Share | 2.70 |
| Price / NCAV | 4.06 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -0.70 |
| Return on Assets (ROA) | -0.48 |
| Return on Equity (ROE) | -0.70 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 11.66 |
| Current Ratio | 11.66 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 456.21 |
| Assets | 458.30 |
| Liabilities | 80.19 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.00 |
| Operating Income | 0.00 |
| Net Income | 0.00 |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | 0.00 |
| Cash from Investing | 0.00 |
| Cash from Financing | 0.00 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G/A | Biotechnology Value Fund L P | |||
| 13G/A | Suvretta Capital Management, Llc | |||
| 13G/A | Janus Henderson Group Plc | |||
| 13D/A | Ra Capital Management, L.p. | |||
| 13G | Deep Track Capital, LP | |||
| 13G/A | Rtw Investments, Lp | 7.00 | 32.26 | |
| 13G/A | BlackRock, Inc. | 7.10 | 0.00 | |
| 13G/A | State Street Corp | 3.10 | -39.78 | |
| 13G/A | Cormorant Asset Management, LP | 0.00 | -100.00 | |
| 13G/A | Adage Capital Partners Gp, L.l.c. | 4.48 | 14.42 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| File Date | Form | SEC Filings |
|---|---|---|
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K | ||
(click for more detail) |
||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 141,871 | 661,875 | 21.43 | |
| 278,667 | 735,417 | 37.89 | |
| 196,055 | 702,484 | 27.91 | |
| 181,428 | 901,322 | 20.13 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| CVAC – CureVac N.V. | EOLS – Evolus, Inc. |
| ESPR – Esperion Therapeutics, Inc. | ETON – Eton Pharmaceuticals, Inc. |
| FATE – Fate Therapeutics, Inc. |
Financial data and stock pages provided by
Fintel.io